This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Slottow, T. L. P. Articles by Waksman, R. Search for Related Content PubMed PubMed Citation Articles by Slottow, T. L. P. Articles by Waksman, R. Related Collections Other Stroke Treatment - Medical

(Circulation. 2007;116:677-682.)
© 2007 American Heart Association, Inc.

New Drugs and Technologies

Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel Meeting on Patent Foramen Ovale Closure Devices

Tina L. Pinto Slottow, MD; Daniel H. Steinberg, MD; Ron Waksman, MD

From the Division of Cardiology, Washington Hospital Center, Washington, DC.

Correspondence to Ron Waksman, MD, Washington Hospital Center, 110 Irving St NW, Suite 4B-1, Washington, DC 20010. E-mail ron.waksman{at}medstar.net

Patent foramen ovales (PFOs) are common congenital cardiac defects that are more prevalent among patients experiencing cryptogenic stroke than among those with strokes of known origin. Medical treatment for these processes is often considered inadequate, and mechanical closure of the PFO is an attractive, albeit controversial, alternative. Although it is plausible that percutaneous PFO closure will reduce the rate of recurrent stroke in these patients, randomized trials examining the efficacy of devices in this setting have not been completed. In 2007, the Food and Drug Administration convened a meeting of the Circulatory System Devices Panel to discuss the necessity of randomized trials, as well as obstacles to trial enrollment and completion.

Key Words: heart septal defects, atrial • stroke • instrumentation

This article has been cited by other articles:

				P. T. O'Gara, S. R. Messe, E. M. Tuzcu, G. Catha, and J. C. Ring Percutaneous Device Closure of Patent Foramen Ovale for Secondary Stroke Prevention: A Call for Completion of Randomized Clinical Trials A Science Advisory From the American Heart Association/American Stroke Association and the American College of Cardiology Foundation The American Academy of Neurology affirms the value of this science advisory J. Am. Coll. Cardiol., May 26, 2009; 53(21): 2014 - 2018. [Abstract] [Full Text] [PDF]

				P. T. O'Gara, S. R. Messe, E. M. Tuzcu, G. Catha, and J. C. Ring Percutaneous Device Closure of Patent Foramen Ovale for Secondary Stroke Prevention: A Call for Completion of Randomized Clinical Trials: A Science Advisory From the American Heart Association/American Stroke Association and the American College of Cardiology Foundation The American Academy of Neurology affirms the value of this science advisory. Circulation, May 26, 2009; 119(20): 2743 - 2747. [Abstract] [Full Text] [PDF]

				S. R. Messe and S. E. Kasner Patent Foramen Ovale in Cryptogenic Stroke: Not to Close Circulation, November 4, 2008; 118(19): 1999 - 2004. [Full Text] [PDF]

				R. Bhindi and O. J. Ormerod Percutaneous Closure of Patent Foramen Ovale and Atrial Septal Defect JAMA, May 21, 2008; 299(19): 2272 - 2272. [Full Text] [PDF]

				C. Stollberger, B. Schneider, and J. Finsterer Letter Regarding Article by Hara et al, "Patent Foramen Ovale Closure by Radiofrequency Thermal Coaptation: First Experience in the Porcine Model and Healing Mechanisms Over Time" Circulation, March 4, 2008; 117(9): e176 - e176. [Full Text] [PDF]

				A. R. Opotowsky, M. J. Landzberg, S. E. Kimmel, and G. D. Webb Trends in the Use of Percutaneous Closure of Patent Foramen Ovale and Atrial Septal Defect in Adults, 1998-2004 JAMA, February 6, 2008; 299(5): 521 - 522. [Full Text] [PDF]

				A. B. Singhal and E. H. Lo Advances in Emerging Nondrug Therapies for Acute Stroke 2007 Stroke, February 1, 2008; 39(2): 289 - 291. [Full Text] [PDF]